Suchergebnisse - "Pinato, David J"

PubPharm (13)

1

Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram

enthalten in: Frontiers in immunology | 2024

von Losurdo, A. | Dipasquale, A. | Giordano, L. | +11

2

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Vithayathil, M. | D'Alessio, A. | Fulgenzi, C. | +32

CommentIn: Liver Int. 2022 Nov;42(11):2352-2353. - PMID 36162086

3

Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

enthalten in: BJU international | 2022

von Makrakis, D. | Talukder, R. | Diamantopoulos, L. | +44

4

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy

enthalten in: Thoracic cancer | 2022

von Banna, G. | Tiseo, M. | Cortinovis, D. | +31

5

Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma : implications for immunotherapy

enthalten in: Journal for immunotherapy of cancer | 2021

von Pinato, D. | Murray, S. | Forner, A. | +18

6

Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma : a comparison of outcomes

enthalten in: BJU international | 2021

von Esagian, S. | Khaki, A. | Diamantopoulos, L. | +43

7

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab

enthalten in: Journal for immunotherapy of cancer | 2021

von Alexander, J. | Ibraheim, H. | Sheth, B. | +20

8

Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis

enthalten in: Journal of hepatology | 2021

von Gudd, C. | Au, L. | Triantafyllou, E. | +17

9

Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2021

von Wong, C. | Fessas, P. | Dominy, K. | +8

10

Post-registration experience of nivolumab in advanced hepatocellular carcinoma : an international study

enthalten in: Journal for immunotherapy of cancer | 2020

von Fessas, P. | Kaseb, A. | Wang, Y. | +24